FTH Stock — Faeth Therapeutics Inc.: Cash, EV, Pipeline

What they do

Our core scientific thesis is that simultaneously suppressing multiple nodes of a pathway produces deeper, more durable tumor suppression than targeting any single-node alone, which we believe may also enable lower drug dosing, potentially contributing to an improved tolerability profile.

Source: 10-K FY2025 via SEC EDGAR

Share price

$14.15

Market cap

$367.8M

Cash

$174.8M

Enterprise value

$193.0M

Balance sheet

Cash	$174.8M
Debt	$0.0M
Net cash	$174.8M
Enterprise value	$193.0M
Basic shares	25.8M shares
Fully diluted shares	29.8M shares
Fully diluted market cap	$421.6M
Cash per share	$6.76
Quarterly burn	$15.7M
Cash runway	11.2 quarters

Cash figures as of 2026-09-30. Database snapshot: 2026-11-10.

Share structure

Common

25.8M

Pre-funded warrants

—

Options

3.4M

RSUs

0.0M

Warrants

0.0M

Converts

0.0M

Conv preferred

0.5M

ESPP reserve

0.0M

FDSO

29.8M

Cap table as of 2026-10-30.

Price history

Loading FTH daily closes…

Loading price history…

Next catalyst

PIK-101 · Est. Jul 2, 2027 · guidance midpoint · guided in 7 wks

Recently reported

Sapanisertib Phase 2 Positive · 2026-11-09

PIK-201

Primary: Confirmed objective response rate (ORR) in efficacy-evaluable patients (PIK-201 topline) — 33% (12 of 36 efficacy-evaluable patients)

· Confirmed ORR in PIK3CA-mutated patients: 44% (7 of 16)

· Disease control rate 83%

· Preliminary median PFS 7.4 months (95% CI 5.3-NR) in all 42 treated patients

· 6-month PFS rate 62%

· Median of 2 prior lines of therapy

Safety: 2 patients (5%) discontinued due to a treatment-related adverse event; no treatment-related deaths; hyperglycemia 12% (2% Grade 3), stomatitis 21% (2% Grade 3); Grade 3 or higher treatment-related adverse events in 64%

Source release →

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
GUIDEDEst. Jul 2, 2027 in 7 wks guidance midpoint	PIK-101 Phase 1b/2 in breast cancer	Phase 1b	breast cancer	2027
Jun 12 - Jul 24 in 31 mo	Serabelisib	Phase 1/2	HR+ HER2- Breast Cancer	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

PIKTOR

Phase 2 · Active Modality: oral multi-node inhibitor

Target PI3K/AKT/mTOR pathway

Partnerships Takeda (agreement; Phase 3 first-dosing equity issuance provision renegotiated and removed in January 2026)

Indications

second-line advanced endometrial cancer (Stage not disclosed)
HR+/HER2- advanced breast cancer (Stage not disclosed)

Catalysts

— None
— None
— None

Status note Lead program following the February 2026 Faeth acquisition (all-oral combination of serabelisib and sapanisertib). First patient dosed in FTH-PIK-101 in April 2026. NEAAR and IEM preclinical programs noted but unnamed as candidates.

solnerstotug

Phase 1 · Active Modality: conditionally active monoclonal antibody

Aliases SNS-101

Target VISTA

Indications

not disclosed (Stage not disclosed)

Status note Legacy program. Company is completing the remaining portion of the Phase 1/2 trial with patients currently on study; no new development plans stated.

Per-asset detail extracted from the 10-Q filed 2026-08-04. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Sapanisertib
Lead indication	Endometrial Cancer
Lead phase	Phase 2
Active trials	2

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06463028	Phase 2	Recruiting	Sponsor	Faeth Therapeutics	—	Endometrial Cancer	—
NCT07558733	Phase 1/2	Recruiting	Sponsor	Faeth Therapeutics	—	HR+ HER2- Breast Cancer	—

Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 2 active trials for Faeth Therapeutics on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
Avoro Capital Advisors	1,444,039	+1,444,039	0.32%	2026-08-14
Baker Bros. Advisors	1,286,411	+1,286,411	0.16%	2026-08-14
Cormorant Asset Management	1,028,242	+722,020	0.39%	2026-08-14
Vivo Capital	722,020	no change	1.65%	2026-08-14
Logos Global Management	722,020	+692,020	0.78%	2026-08-14
RA Capital Management	722,020	+722,020	0.16%	2026-08-14
ADAR1 Capital Management	361,010	+361,010	0.42%	2026-08-14
Boxer Capital	180,505	+180,505	0.34%	2026-08-14
Ikarian Capital	35,386	+29,035	0.14%	2026-08-14

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

FTH — Faeth Therapeutics Inc. ☆

What they do

Balance sheet

Share structure

Price history

Next catalyst

Recently reported

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Specialist fund holders

Latest news

FTH — Faeth Therapeutics Inc.